Kiora Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Balance Sheet Information

Balance Sheet Information

3 Months Ended

Mar. 31, 2022

Balance Sheet Information

Balance Sheet Information

2. Balance Sheet Information

Cash, Cash Equivalents and Restricted Cash

A summary of cash and cash equivalents and restricted cash is as follows:


	March 31, 2022
	(unaudited)		December 31, 2021
Cash and Cash Equivalents	$	5,067,354	$	7,854,690
Restricted Cash, Non-current		45,000		45,000
Total Cash, Cash Equivalents and Restricted Cash	$	5,112,354	$	7,899,690

Noncurrent restricted cash consists of an deposit with a financial institution for corporate credit card.

Accrued Expenses

Accrued expenses consist of the following:


	March 31, 2022
	(unaudited)		December 31, 2021
Executive Severance	$	1,049,808	$	200,605
Payroll and Benefits		336,680		737,365
Professional Fees		384,452		194,425
Clinical Trials		61,994		168,785
Other		—		28,961
Total Accrued Expenses	$	1,832,934	$	1,330,141

For the three months ended March 31, 2022, executive severance increased due to a one-time severance benefit accrual of $0.963 million for the Company’s previous Chief Executive Officer.